Your session is about to expire
← Back to Search
Unknown
A Study of AG-80308 in Dry Eye Patients
Phase 1
Waitlist Available
Research Sponsored by Allgenesis Biotherapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests AG-80308 eye drops in patients with dry eye to see if it helps lubricate their eyes and reduce discomfort.
Eligible Conditions
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Group 4Experimental Treatment1 Intervention
One drop of 0.03% AG-80308, new formulation, two times daily to both eyes for 3 months
Group II: Group 3Experimental Treatment1 Intervention
One drop of 0.1% AG-80308, two times daily to both eyes for 3 months
Group III: Group 2Experimental Treatment1 Intervention
One drop of 0.03% AG-80308, two times daily to both eyes for 3 months
Group IV: Group 1Experimental Treatment1 Intervention
One drop of 0.001% AG-80308, two times daily to both eyes for 3 months
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AG-80308
2022
Completed Phase 1
~90
Find a Location
Who is running the clinical trial?
Allgenesis Biotherapeutics Inc.Lead Sponsor
2 Previous Clinical Trials
89 Total Patients Enrolled
ORA, Inc.Industry Sponsor
69 Previous Clinical Trials
8,875 Total Patients Enrolled